Dihydro-β-erythroidine is a a competitive nicotinic receptor antagonist. Dihydro-β-erythroidine blocks the discriminative stimulus properties of nicotine. Dihydro-β-erythroidine inhibits the anxiolytic effect of nicotine induced[1][2].
Definition
ChEBI: An organic heterotetracyclic compound resulting from the partial hydrogenation of the 1,3-diene moiety of beta-erythroidine to give the corresponding 2-ene.
in vivo
Dihydro-β-erythroidine (0.5, 1.6, 5.0 mg/kg; s.c.) blocks the discriminative stimulus properties of nicotine in rats[1].
Dihydro-β-erythroidine (100 ng) shows antagonism of the anxiolytic effect of nicotine in the dorsal raphe′ nucleus in rats[2].
Animal Model:
200-250 g male hooded Lister rats[1]
Dosage:
0.5, 1.6, 5.0 mg/kg
Administration:
S.c.
Result:
Prevented the development of CTAs (conditioned taste aversion) and blocked the discriminative stimulus effect of nicotine (0.2 or 0.4 mg/kg SC) for 45 min after its administration.
References
[1] Shoaib M, et al. Antagonism of stimulus properties of nicotine by dihydro-beta-erythroidine (DHbetaE) in rats. Psychopharmacology (Berl). 2000 Apr;149(2):140-6. DOI:10.1007/s002139900348 [2] Cheeta S, et al. Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. Pharmacol Biochem Behav. 2001 Dec;70(4):491-6. DOI:10.1016/s0091-3057(01)00641-4
